About Us

Print E-mail
By BioMedReports.Com   
BioMedReports.com was co-founded by M.E. Garza and Mike Havrilla in early 2009. Both were successful traders and investors who had historically made some of their best trades in the healthcare/biotech sector. They decided to join up to share their knowledge and expertise about the sector with other investors.

biotech trading

M.E. Garza launched BiomedReports after he saw an opportunity to cover the sector like never before. A two-time Emmy Award nominated television producer and successful entrepreneur, Garza's background in media, writing, marketing and public affairs has allowed him to establish and lead various companies in the broadband, entertainment and communications fields. He currently resides in Los Angeles and his passion is tracking the latest advances in healthcare and technology- which gives him "great hope and promise" for the future of mankind. He is a constant student of the market who believes that the biotech sector is completely unique and dynamic sector- where everything from research to financial models and the rules for market analysis from other sectors just don't apply. He has guided BioMedReports into a leading publication that helps investors realize the potential of this revolution in finance and science, while shining the spotlight on companies that are attempting to change our lives in so many ways.  Email M.E. Garza

BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.


Content from this website is syndicated througout the world via various news wires and syndicating partners including Market Wire, ThomsonReuters,Financial Content Services, Inc., and others. Publishers interested in re-publishing our content may do so free of licence fees and royalties by contacting us electronically or via post at our offices, located at the Los Angeles Center Studios:


BioMedReports
c/o M. Media
1201 W. 5th Street
Suite F-105

Los Angeles, CA 90017

 

 

The terms of service for BioMedReports.com include a non-refundable payment of $199 for premium access to the FDA Calendar for a period of one year. Also, users understand and agree that the dates appearing in the FDA Calendar are obtained through reliable, public sources such as company press releases and SEC filings, but are not endorsed or affiliated with the FDA or by any of the companies appearing in the calendars. The authors of this site shall not be held liable for any trading losses which occur as a result of the estimated decision dates or other information included in the FDA Calendar or elsewhere on this website. All of the dates included in the FDA Calendar and other opinions appearing on this website should be used for informational purposes only and should not be construed as specific trading or investing advice.


We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our reports is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Please note that our writers, analysts and site administrators all reserve the right, without prior notice, to sell, buy, cover, liquidate, increase or decrease any positions disclosed in any of the securities covered or written about on this news portal at any time, for any reason. BioMedReport.Com's directors, officers and employees may anticipate purchasing shares mentioned in this report or may already have purchased shares and may profit in the event those shares rise in value. We reserve the right to buy or sell the shares of any companies mentioned in any reports or materials published on this portal at any time.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.


© BioMedReports.Com. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor. The contributors on this website are not chartered financial analysts and we do not provide individual investment advice.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BioMedReports OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA: Below is a look at som... http://t.co/ZkvEC7x99Y
BioMedReports Soaring generic drug prices draw Senate scrutiny... http://t.co/Fzq7h0GODI
BioMedReports Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial; Marina and Mirna Amend License A... http://t.co/l3kFbpKB92
Benzinga.com supporter Seeking Alpha Certified